**New Drugs for Rare Diseases Set to Launch in India**
Four new medications targeting rare diseases are on the verge of being launched, while five treatments for seven specific conditions have already been made available, according to Dr. VK Paul, a member of Niti Aayog (health). Speaking at a recent event in New Delhi, Dr. Paul highlighted the significant impact of generic drugs produced by local companies, which have resulted in substantial savings for patients suffering from rare diseases.
Currently, the National Policy for Rare Diseases recognizes 63 conditions, as recommended by the Central Technical Committee for Rare Diseases (CTCRD). Dr. Paul noted that progress has been made in treating seven diseases, including Thalassemia, Wilson’s disease, and Cystic Fibrosis, with five drugs now accessible to patients. He also mentioned that four additional drugs are in development.
In 2023, NITI Aayog identified 13 disorders as priority areas for further research and treatment. Amit Agrawal, Secretary of the Department of Pharmaceuticals, stated that the government has successfully supported the production of drugs for eight rare diseases under the Production-Linked Incentive (PLI) scheme. He emphasized that addressing rare diseases and orphan drugs is a strategic priority for the government, which aims to provide enhanced policy support in this area.
Amitabh Dube, Managing Director and Country President of Novartis, pointed out that rare diseases affect over 300 million people worldwide, with an estimated 70-90 million cases in India alone. While acknowledging the progress made, he stressed the importance of ongoing efforts to tackle the challenges faced by patients in managing rare diseases. Dube called for the creation of an ecosystem that fosters research and development, minimizes regulatory delays, and promotes innovation, ensuring that treatments reach Indian patients more swiftly. He also advocated for sustainable financing solutions to improve access to advanced therapies that may cost over ₹50 lakh.
In conclusion, the advancements in the treatment of rare diseases in India signal a positive shift towards better healthcare solutions for affected patients. Continued collaboration between the government, pharmaceutical companies, and healthcare providers will be essential in overcoming the challenges that remain.
**FAQ**
**What are the new drugs for rare diseases in India?**
Four new medications are expected to launch soon, while five treatments for seven rare diseases, including Thalassemia and Cystic Fibrosis, are already available.
